idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
15.11.2023 16:50

Nanoparticles for optimized cancer therapy

Dr. Carmen Rotte Kommunikation & Medien
Max-Planck-Institut für Multidisziplinäre Naturwissenschaften

    Researchers from Göttingen and Karlsruhe have developed a new treatment approach for pancreatic cancer. The innovative method promises to be able to treat the disease in a more targeted way and with fewer side effects in the future. The therapy is now to be optimized for clinical application as quickly as possible.

    Pancreatic cancer is one of the deadliest types of cancers in humans. It is the fourth leading cause of cancer-related deaths in the western world. The early stages of the disease often progress without symptoms, so diagnosis is usually very late. Another problem: Advanced tumors – and their metastases – can no longer be completely removed. Chemotherapies, in turn, attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely.

    An interdisciplinary research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology (KIT) have developed a method that promises to treat pancreatic carcinomas with more accuracy and with fewer side effects than current cancer therapies. Using so-called nanoparticles, they transported the active substance Gemcitabine in large quantities directly into the tumor.

    Reduce side effects

    “Targeting the drug in high concentrations into the tumor cells with the help of the nanoparticles increases the efficacy and spares healthy cells. This can reduce the severe side effects that occur with Gemcitabine,” explains Myrto Ischyropoulou, lead author of the study recently published in the journal Advanced Materials. “Currently, patients are given the free drug. This is distributed throughout the body and can lead to toxic effects in all parts of the body. The nanoparticles, on the other hand, release the drug mainly in the tumor.” Joanna Napp, scientist at the UMG, adds: “Using imaging methods, we have already been able to demonstrate in mouse models that the nanoparticles accumulate in the tumors.”

    Effective new therapeutic approach

    The administration of nanoparticles also allows resistance mechanisms in the tumor to be circumvented. “Free Gemcitabine is often no longer taken up by the tumor very early on and is thus largely ineffective there. However, it still leads to considerable side effects, for example in the liver and kidneys,” explains Claus Feldmann from KIT. “By using a different uptake mechanism in tumor cells, our nanoparticles could be a very effective new therapeutic approach here.”

    The research success is an excellent example of successful interdisciplinary cooperation, says Frauke Alves, group leader at the MPI and the UMG. “From the idea to the development of the new nanoparticles to preclinical testing, chemists, biologists, pharmacists, and physicians have worked hand in hand.” With a spin-off, the scientists are now working to bring their new nanoparticles out of the test phase and into clinical use as quickly as possible.


    Wissenschaftliche Ansprechpartner:

    Prof. Dr. Frauke Alves
    Research Group Leader at the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, Germany
    phone: +49 551 201-31655
    e-Mail: falves@gwdg.de


    Originalpublikation:

    Ischyropoulou, M.; Sabljo, K.; Schneider, L.; Niemeyer, C. M.; Napp, J.; Feldmann, C.; & Alves, F.: High-load Gemcitabine inorganic-organic hybrid nanoparticles as image-guided tumor-selective drug-delivery system to treat pancreatic cancer, Advanced Materials, 16. August 2023.
    https://doi.org/10.1002/adma.202305151


    Weitere Informationen:

    https://www.mpinat.mpg.de/4552645/pr_2320 – Original press release
    https://www.mpinat.mpg.de/alves – Research Group Translational Molecular Imaging of Frauke Alves at the Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany


    Bilder

    A tumor under the fluorescence microscope: The tissue of this pancreatic tumor in a mouse glows green, the nanoparticles orange.
    A tumor under the fluorescence microscope: The tissue of this pancreatic tumor in a mouse glows gree ...

    Myrto Ischyropoulou / Max Planck Institute for Multidisciplinary Sciences


    Merkmale dieser Pressemitteilung:
    Journalisten, Wissenschaftler, jedermann
    Biologie, Medizin
    überregional
    Forschungsergebnisse, Wissenschaftliche Publikationen
    Englisch


     

    A tumor under the fluorescence microscope: The tissue of this pancreatic tumor in a mouse glows green, the nanoparticles orange.


    Zum Download

    x

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).